IOBT Profile
IO Biotech, Inc. is a clinical-stage biopharmaceutical company focused on developing immune-modulating therapies for cancer treatment. Utilizing its proprietary T-win technology platform, IO Biotech aims to address various immunosuppressive mechanisms that hinder effective cancer treatment. The company's flagship product candidate, IO102-IO103, is designed to target key immunosuppressive proteins such as Indoleamine 2,3-dehydrogenase (IDO) and programmed death-ligand 1 (PD-L1). This therapeutic candidate is currently undergoing Phase 2 clinical trials for melanoma and Phase 1 trials for a range of cancers, including lung, head and neck, bladder, and melanoma.
Another significant asset in IO Biotech's pipeline is IO112, a therapeutic candidate that features a single peptide derived from Arginase 1. This product is designed to target T cells that recognize epitopes associated with Arginase 1, aiming to enhance immune response against cancer cells. The development of IO112 represents a novel approach in targeting specific immune mechanisms to improve cancer treatment outcomes.
The company’s research and development efforts are concentrated on harnessing the power of its T-win technology to develop innovative therapies that can overcome current limitations in cancer immunotherapy. By focusing on immune modulation, IO Biotech seeks to enhance the effectiveness of existing treatments and provide new options for patients with challenging cancer types.
Founded in 2014 and headquartered in Copenhagen, Denmark, IO Biotech is at the forefront of advancing cancer immunotherapy. The company's commitment to developing cutting-edge therapies reflects its dedication to addressing critical needs in oncology and improving patient outcomes through targeted immune interventions.
|
